Commonwealth Equity Services
NRSN icon

Commonwealth Equity Services’s NeuroSense Therapeutics NRSN Stock Holding History

Commonwealth Equity Services’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1,139
Closed -$16.4K – 4501
2026
Q2 		$16.4K Hold
1,139
– – ﹤0.01% 4378
2026
Q1 		$17.2K Hold
1,139
– – ﹤0.01% 4262
2025
Q4 		$17.5K Buy
1,139
+85
+8% +$1.79K ﹤0.01% 4248
2025
Q3 		$26K Hold
1,054
– – ﹤0.01% 4197
2025
Q2 		$40K Buy
1,054
+191
+22% +$5.54K ﹤0.01% 4180
2025
Q1 		$16K Buy
863
+50
+6% +$1.11K ﹤0.01% 4134
2024
Q4 		$20K Buy
813
+182
+29% +$4.19K ﹤0.01% 4041
2024
Q3 		$16K Buy
+631
New +$12K ﹤0.01% 4012

Other funds holding NRSN

PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Commonwealth Equity Services's NRSN Position: Q3 2026 in Review

Commonwealth Equity Services sold out of NeuroSense Therapeutics (NRSN) in Q3 2026, closing a stake of 1,139 shares — an estimated $16.4K sold.

Commonwealth Equity Services first reported a position in NRSN in Q3 2024 and held it in 8 quarters. The position peaked at $40K in Q2 2025. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

  • Commonwealth Equity Services reported no remaining NeuroSense Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 1,139 NeuroSense Therapeutics shares in Q3 2026, an estimated $16.4K.
  • Commonwealth Equity Services first reported a position in NeuroSense Therapeutics in Q3 2024 and held it in 8 quarters.
  • Commonwealth Equity Services's NeuroSense Therapeutics position peaked at $40K in Q2 2025.
  • 4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on Commonwealth Equity Services's 13F filing for Q3 2026, filed 2 Nov 2026.